• Experimental nanomedicine targets KRAS G12D mutation in metastatic colorectal cancer

    Preclinical research describes a macrophage-hitchhiking delivery system combining gemcitabine and a KRAS G12D inhibitor that improved drug delivery to lung metastases and triggered immune responses in colorectal cancer models. (Journal of Controlled Release)